Bristol Myers Squibb Announces Results from the Phase 3 Randomized Trial Evaluating Opdivo Plus Yervoy

Bristol Myers Squibb announced results from the Phase 3 CheckMate -8HW trial evaluating Opdivo plus Yervoy compared to investigator?s choice of chemotherapy as a first-line treatment for patients...

Related Keywords

United States ,American ,Yervoy Opdivo ,Bristol Myers Squibb ,American Society Of Clinical Oncology ,Blinded Independent Central Review ,Hazard Ratio ,Confidence Interval ,Clinical Oncology ,Gastrointestinal Cancers Symposium ,Myers Squibb ,Bristol Myers ,Markets ,